Search Results - "Wahl, Jonathan L"

Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia by Fathi, Amir T, Kim, Haesook T, Soiffer, Robert J, Levis, Mark J, Li, Shuli, Kim, Annette S, DeFilipp, Zachariah, El-Jawahri, Areej, McAfee, Steve L, Brunner, Andrew M, Amrein, Philip C, Mims, Alice S, Knight, Laura W, Kelley, Devon, Bottoms, Aj S, Perry, Lindsey H, Wahl, Jonathan L, Brock, Jennifer, Breton, Elayne, Marchione, Dylan M, Ho, Vincent T, Chen, Yi-Bin

“…Isocitrate dehydrogenase 1 (IDH1) mutations occur in 5% to 10% of patients with acute myeloid leukemia (AML). Ivosidenib is an IDH1 inhibitor, approved for use…”
Get full text

Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies by Fathi, Amir T., Kim, Haesook T., Soiffer, Robert J., Levis, Mark J., Li, Shuli, Kim, Annette S., Mims, Alice S., DeFilipp, Zachariah, El-Jawahri, Areej, McAfee, Steven L., Brunner, Andrew M., Narayan, Rupa, Knight, Laura W., Kelley, Devon, Bottoms, AJ S., Perry, Lindsey H., Wahl, Jonathan L., Brock, Jennifer, Breton, Elayne, Ho, Vincent T., Chen, Yi-Bin

“…•Enasidenib is well-tolerated as maintenance therapy following hematopoietic cell transplantation for IDH2-mutated myeloid malignancies.•Relapse rate was low…”
Get full text

A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for IDH2-Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation by Fathi, Amir T., Li, Shuli, Soiffer, Robert J., Levis, Mark, Mims, Alice S., Devine, Steven M, Defilipp, Zachariah, El-Jawahri, Areej, McAfee, Steven L., Spitzer, Thomas R., Frigault, Matthew J, Dey, Bimalangshu R., Amrein, Philip C., Hobbs, Gabriela S., Brunner, Andrew M., Hock, Hanno R., Narayan, Rupa, Knight, Laura W., Kelley, Devon, Bottoms, AJ S., Brown, Jami L., Del Rio, Candice J., Vanderklish, Julie E., Danielson, Colleen, Saylor, Meredith L., Hunnewell, Chrisa L., Perry, Lindsey H., Wahl, Jonathan L., Breton, Elayne, Ho, Vincent T., Chen, Yi-Bin

“…Characterization of molecular alterations in acute myeloid leukemia (AML) has led to development of targeted therapies, including FLT3 and IDH1/2 inhibitors…”
Get full text

Efficacy and Safety of 1% Progesterone Gel to the Forehead for Ocular Chronic Graft-versus-Host Disease by Luo, Zhonghui K., Domenech-Estarellas, Edgar A., Han, Amy, Lee, Do, Khatri, Ram, Wahl, Jonathan L., Cutler, Corey, Armand, Philippe, Antin, Joseph H., Koreth, John, Gooptu, Mahasweta, Alyea, Edwin P., Soiffer, Robert J., Ho, Vincent T.

“…•Forehead application of 1% progesterone gel alleviates signs and symptoms of ocular graft-versus-host disease within 10 weeks.•Improvements occur in the…”
Get full text